Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

19.0%

4 terminated/withdrawn out of 21 trials

Success Rate

69.2%

-17.3% vs industry average

Late-Stage Pipeline

33%

7 trials in Phase 3/4

Results Transparency

33%

3 of 9 completed trials have results

Key Signals

3 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

6(40.0%)

Phase 3

4(26.7%)

Phase 4

3(20.0%)

N/A

1(6.7%)

Phase 1

1(6.7%)

15Total

Phase 2(6)

Phase 3(4)

Phase 4(3)

N/A(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials

NCT07419373Phase 2Recruiting

ARN-75039 Lassa Fever Treatment in West Africa

Role: collaborator

NCT06212336Phase 2Recruiting

ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Role: collaborator

NCT05959421Phase 3Not Yet Recruiting

Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure

Role: collaborator

NCT06222723Phase 2Recruiting

LAssa Fever Adjunct Treatment With DEXamethasone

Role: lead

NCT03655561Active Not Recruiting

Lassa Fever Clinical Course and Prognostic Factors in Nigeria

Role: collaborator

NCT03671109Phase 3Completed

Improving Maternal heAlth by Reducing Malaria in African HIV Women

Role: collaborator

NCT05303168Completed

Prevalence and Impact of COVID-19 on Maternal and Infant Health in African Populations

Role: collaborator

NCT04907682Phase 2Completed

Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever

Role: lead

NCT05047666Unknown

COVID-Like Illness Respiratory Pathogens. A Prospective Cohort on the COVID-19 Post-acute Condition

Role: lead

NCT04050566Unknown

Malaria Birth Cohort (MBC) in Agogo, Ghana

Role: lead

NCT01897909Completed

The Impact of Helicobacter Pylori Infection on Immune Regulation and Clinical Course in HIV Patients in Ghana

Role: lead

NCT01853657Not ApplicableUnknown

Kumasi Cohort Study

Role: lead

NCT04912284Completed

Africa COVID-19 Vaccine Hesitancy

Role: lead

NCT04342221Phase 3Terminated

Hydroxychloroquine for COVID-19

Role: collaborator

NCT04205669Phase 4Completed

Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon

Role: collaborator

NCT04340544Phase 2Terminated

Hydroxychloroquine for the Treatment of Mild COVID-19 Disease

Role: collaborator

NCT03615911Phase 1Completed

Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S

Role: collaborator

NCT01714414Phase 2Completed

A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen

Role: collaborator

NCT01143272Phase 3Terminated

Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea

Role: lead

NCT00206739Phase 4Completed

Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infants

Role: lead